Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Molecules ; 27(23)2022 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-36500493

RESUMO

Tenofovir alafenamide (TAF) is an antiretroviral (ARV) drug that is used for the management and prevention of human immunodeficiency virus (HIV). The clinical availability of ARV delivery systems that provide long-lasting protection against HIV transmission is lacking. There is a dire need to formulate nanocarrier systems that can help in revolutionizing the way to fight against HIV/AIDS. Here, we aimed to synthesize a polymer using chitosan and polyethylene glycol (PEG) by the PEGylation of chitosan at the hydroxyl group. After successful modification and confirmation by FTIR, XRD, and SEM, TAF-loaded PEGylated chitosan nanoparticles were prepared and analyzed for their particle size, zeta potential, morphology, crystallinity, chemical interactions, entrapment efficacy, drug loading, in vitro drug release, and release kinetic modeling. The fabricated nanoparticles were found to be in a nanosized range (219.6 nm), with ~90% entrapment efficacy, ~14% drug loading, and a spherical uniform distribution. The FTIR analysis confirmed the successful synthesis of PEGylated chitosan and nanoparticles. The in vitro analysis showed ~60% of the drug was released from the PEGylated polymeric reservoir system within 48 h at pH 7.4. The drug release kinetics were depicted by the Korsmeyer-Peppas release model with thermodynamically nonspontaneous drug release. Conclusively, PEGylated chitosan has the potential to deliver TAF from a nanocarrier system, and in the future, cytotoxicity and in vivo studies can be performed to further authenticate the synthesized polymer.


Assuntos
Quitosana , Infecções por HIV , Nanopartículas , Humanos , Quitosana/química , Nanopartículas/química , Polietilenoglicóis/química , Liberação Controlada de Fármacos , Tamanho da Partícula , Adenina , Portadores de Fármacos/química
2.
Pak J Pharm Sci ; 34(6(Supplementary)): 2357-2364, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35039274

RESUMO

The current study was conducted to fabricate Metoclopramide HCL (MCH) and Sumatriptan succinate (SS) instant release buccal films (IRBF) without using any super disintegrant. The solvent casting method was used for the preparation of IRBFs and prepared IRBFs were physicochemically evaluated. Spectrophotometric analysis was done to determine the lambda max followed by the linearity determination of both drugs. Different concentrations such as 100, 125, and 150mg of hydrophilic polymer (HPMC E5) were employed but the concentration of glycerol was variable. Comparatively better results were observed for the formulation with 150mg of HPMC E5 and 30% glycerol. Formulated IRBFs showed good tensile strength with a mean disintegration time of 12.4-28.4 seconds and rapid dissolution with more than 50% drug release within 2 minutes. It was concluded that the chosen combination of polymers was appropriate for the fabrication of MCH and SS buccal strips.


Assuntos
Antagonistas dos Receptores de Dopamina D2/química , Glicerol/química , Derivados da Hipromelose/química , Metoclopramida/química , Agonistas do Receptor 5-HT1 de Serotonina/química , Sumatriptana/química , Administração Bucal , Antagonistas dos Receptores de Dopamina D2/administração & dosagem , Formas de Dosagem , Composição de Medicamentos , Liberação Controlada de Fármacos , Cinética , Metoclopramida/administração & dosagem , Agonistas do Receptor 5-HT1 de Serotonina/administração & dosagem , Solubilidade , Espectrofotometria Ultravioleta , Sumatriptana/administração & dosagem , Resistência à Tração
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA